Jubilant Life Sciences’ - Bengaluru-based subsidiary - Jubilant Biosys, has informed USFDA acceptance of the Investigational New Drug (IND) filing for a novel molecule targeting prostate cancer with Endo Pharmaceuticals of the US. This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013.
The multi-target oncology collaboration between Jubilant and Endo began four years ago, and is focused on developing best-in-class, differentiated therapies that address the unmet needs of cancer patients worldwide. The collaboration has delivered on multiple milestones across the discovery continuum.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
